Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SNA-EBV
- Development stage
- Preclinical
- Lead developer
- Labo'Life
- Administration
- Sublingual
01
Overview
**SNA-EBV** is a proprietary specific-nucleic-acid preparation used as an ultra-low-dose homeopathic micro-immunotherapy ingredient directed toward Epstein-Barr virus-associated conditions. It is not established as an independently marketed single-agent medicine; rather, it is a constituent of Labo'Life's multi-ingredient product 2LEBV, alongside ultra-low-dose interleukin-1, interleukin-2, DNA, RNA, and SNA-HLA II. The intended role is immunomodulation in Epstein-Barr virus infection, but a discrete molecular target and independently validated mechanism for SNA-EBV have not been established in public sources.
- Other names
- Specific Nucleic Acid SNA-EBVSpecific Nucleic Acid – Epstein-Barr Virus
Beyond the preview
Go deeper on SNA-EBV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SNA-EBV.